Albion Financial Group Halozyme Therapeutics, Inc. Transaction History
Albion Financial Group
- $1.61 Billion
- Q3 2025
A detailed history of Albion Financial Group transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Albion Financial Group holds 26 shares of HALO stock, worth $1,680. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26Holding current value
$1,680% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
629Shares Held
127MCall Options Held
408KPut Options Held
384K-
Black Rock Inc. New York, NY17.6MShares$1.14 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$791 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$384 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$224 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$220 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...